Jazz Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2004
Net Income	330.79	414.83	-224.06	-329.67	238.62	523.37	Upgrade
Depreciation & Amortization	644.72	638.7	629.47	552.48	278.25	370.16	Upgrade
Share-Based Compensation	231.93	226.84	222	189.01	121	110.56	Upgrade
Other Operating Activities	-168.92	-188.36	644.57	366.69	261.78	-227.69	Upgrade
Operating Cash Flow	1,039	1,092	1,272	778.51	899.65	776.4	Upgrade
Operating Cash Flow Growth	-24.95%	-14.15%	63.39%	-13.47%	15.87%	-2.82%	Upgrade
Capital Expenditures	-27.04	-23.96	-29.05	-27.64	-15	-25.93	Upgrade
Acquisitions	0	0	53	-6,234.79	14.26	-55.07	Upgrade
Change in Investments	-375.1	-120.1	-1.04	1,068	-642.68	67.9	Upgrade
Other Investing Activities	-28	-19	-469.15	-17.89	-364.25	-142.2	Upgrade
Investing Cash Flow	-430.14	-163.06	-446.23	-5,212.14	-1,007.67	-155.3	Upgrade
Share Issuance / Repurchase	-326.74	-320.71	-45.5	-35.6	-163.41	-318.19	Upgrade
Debt Issued / Paid	-31	-31	-582.01	3,871	591.81	-33.39	Upgrade
Other Financing Activities	25.73	46.46	98.02	135.26	99.68	57.83	Upgrade
Financing Cash Flow	-332.02	-305.25	-529.49	3,971	528.07	-293.75	Upgrade
Exchange Rate Effect	-0.89	1.14	-6.22	-3.21	0.37	0.37	Upgrade
Net Cash Flow	275.47	624.83	290.03	-466.32	420.43	327.72	Upgrade
Free Cash Flow	1,011	1,068	1,243	750.87	884.64	750.48	Upgrade
Free Cash Flow Growth	-25.80%	-14.07%	65.53%	-15.12%	17.88%	-9.19%	Upgrade
Free Cash Flow Margin	26.32%	27.86%	33.97%	24.27%	37.43%	34.72%	Upgrade
Free Cash Flow Per Share	16.17	16.88	19.87	12.58	15.88	13.22	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).